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Autosomal dominant polycystic kidney disease 
(ADPKD) is the most common genetic disease in adults, 
with an estimated prevalence of 1 in 500–2,500 (refs1–4). 
Cyst development starts early in life, and macroscopic 
cysts can become detectable in childhood. Substantial 
disease burden with massively enlarged kidneys or 
decreased glomerular filtration rate (GFR) usually does 
not occur until adulthood5; however, approximately 3% 
of children who carry ADPKD- causing mutations have 
either very- early-onset or unusually rapid progressive 
disease5–7. Thus, the absolute incidence of symptomatic 
ADPKD in childhood is thought to be higher than that 
of other severe paediatric kidney diseases such as auto-
somal recessive polycystic kidney disease (~1 in 20,000), 
nephrotic syndrome (~1 in 50,000)8 or haemolytic 
uraemic syndrome (~1 in 100,000 children)9.
The past 25 years have seen remarkable progress in 
knowledge of ADPKD. Advances have been made in 
unravelling the genetic origins of the disease, in non- 
invasive monitoring and in predicting disease pro-
gression; multiple large- scale clinical trials have been 
conducted; and the first pharmacological treatment for 
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Abstract | These recommendations were systematically developed on behalf of the Network for 
Early Onset Cystic Kidney Disease (NEOCYST) by an international group of experts in autosomal 
dominant polycystic kidney disease (ADPKD) from paediatric and adult nephrology , human 
genetics, paediatric radiology and ethics specialties together with patient representatives. 
They have been endorsed by the International Pediatric Nephrology Association (IPNA) and the 
European Society of Paediatric Nephrology (ESPN). For asymptomatic minors at risk of ADPKD, 
ongoing surveillance (repeated screening for treatable disease manifestations without diagnostic 
testing) or immediate diagnostic screening are equally valid clinical approaches. Ultrasonography 
is the current radiological method of choice for screening. Sonographic detection of one or more 
cysts in an at- risk child is highly suggestive of ADPKD, but a negative scan cannot rule out ADPKD 
in childhood. Genetic testing is recommended for infants with very- early-onset symptomatic 
disease and for children with a negative family history and progressive disease. Children with a 
positive family history and either confirmed or unknown disease status should be monitored for 
hypertension (preferably by ambulatory blood pressure monitoring) and albuminuria. Currently, 
vasopressin antagonists should not be offered routinely but off- label use can be considered in 
selected children. No consensus was reached on the use of statins, but mTOR inhibitors and 
somatostatin analogues are not recommended. Children with ADPKD should be strongly 
encouraged to achieve the low dietary salt intake that is recommended for all children.
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slowing disease progression — the vasopressin antago-
nist tolvaptan — has been licensed in the USA, Europe 
and Japan10. However, most ADPKD studies have been 
performed in adults, and their results are not always 
easily transferable to children.
Children with ADPKD constitute a mixed cohort of 
healthy individuals who may not require treatment for 
decades (referred to here as asymptomatic patients) and 
individuals who have disease manifestations, such as 
hypertension, and will benefit from treatment started as 
early as possible. Few children suffer from symptomatic 
disease manifestations such as pain, enuresis, haematuria 
or urinary tract or cyst infections. Both symptomatic 
and asymptomatic children are likely to be confronted 
with the effects of ADPKD in older relatives and to have 
questions or anxieties about their own future health. 
In addition, many children with an affected parent are 
unaware of their own disease status (referred to here as 
at- risk children), either because diagnostic testing has 
not been performed or because a negative ultrasonog-
raphy scan does not exclude ADPKD in childhood. 
An important dilemma in the medical care of children 
with ADPKD is the balance between not medicalizing 
currently healthy individuals and not missing treat-
able disease manifestations in those affected at an early 
age. Medical professionals from different backgrounds, 
nurses, affected parents and at- risk children naturally 
have different views on where this balance lies.
The objective of this Consensus Statement is to pro-
vide clinical guidance on counselling, diagnosing and 
monitoring children with ADPKD in light of the current 
evidence and a multi- stakeholder discussion of ethical 
issues surrounding early diagnosis and monitoring.
Methods
The consensus process was initiated by the Network for 
Early Onset Cystic Kidney Disease (NEOCYST), which 
is a consortium of clinical, genetic and translational 
researchers devoted to the study of early- onset cystic 
kidney diseases11. In addition to paediatric nephrolo-
gists from the consortium, external experts in paediatric 
ADPKD, adult ADPKD, cystic kidney disease genetics, 
paediatric radiology and patient representatives were 
invited to participate (Supplementary information). 
C.G., M.C., R.D.P., R.T., J.K., M.D.S., J.K., A.M.M., 
A.T. and D.M. prepared systematic literature reviews 
in advance of the consensus conference held on 1 
December 2017 in Leuven, Belgium. Tabulated results of 
the literature reviews are included in the Supplementary 
information.
Initial recommendations were developed during the 
conference by discussion in thematic workgroups and 
plenary sessions. Evidence and recommendations were 
graded according to the method used in the current 
American Academy of Pediatrics (AAP) guidelines12,13 
(fig. 1). The grading of recommendations into strong, 
moderate and weak recommendations takes into account 
not only the quality of the evidence but also the balance 
of potential benefits and harms assessed by the con-
sensus group12. The preliminary results of the consen-
sus meeting were presented on 2 December 2017 at an 
international symposium on ‘Management of Polycystic 
Kidney Diseases from Childhood to Adulthood’ in 
Leuven, Belgium, where 104 participants voted live and 
anonymously on the major drafted recommendations. A 
first written draft was compiled by C.G. and reviewed by 
all members of the consensus group. Consequently, two 
rounds of anonymous voting were performed using the 
Delphi method until each recommendation reached at 
least 70% support. The results of the symposium votes 
and the Delphi votes are presented in the Supplementary 
information.
The final draft of the Consensus Statement was 
endorsed by the council of the International Pediatric 
Nephrology Association (IPNA) and the European 
Society of Paediatric Nephrology (ESPN) after thor-
ough review by members of the ESPN Workgroup for 
inherited kidney diseases. The manuscript was also 
reviewed by ADPKD experts from the European Rare 
Kidney Disease Reference Network (ERKNet), whose 
helpful comments were incorporated. Suggestions 
for further research are listed in the Supplementary 
information.
Screening in at- risk minors
The question of whether to screen at- risk children of 
parents affected by ADPKD is a regularly encountered 
but often contentious clinical issue14. Both genetic test-
ing and ultrasonography screening should be considered 
diagnostic and require prior counselling (Box 1).
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Counselling
Uncertainty about a child’s disease status causes a high 
psychological burden for many families15. Parents of at- 
risk children should be informed about the possibilities, 
limits and consequences of genetic and clinical testing 
of their children by appropriately skilled personnel. 
They should understand that screening examinations 
do not always yield definitive results and importantly 
that a normal kidney ultrasonography scan has a low 
negative predictive value in children. Offering diagnostic 
screening does not imply that this screening is advised 
but provides parents with the opportunity to make an 
informed choice. As time for non- directional genetic 
counselling may be limited in general practice and adult 
nephrological care, referral to a geneticist or specialized 
ADPKD clinic may be required. In the case of a child 
being presented to a paediatric nephrology clinic for 
testing, adequate parental understanding of the ethical 
issues should be confirmed before screening. Reliable 
external information, such as patient support groups, 
can also help in decision- making.
An important argument against diagnostic testing 
for ADPKD in childhood is respecting the autonomy 
of the children or young adults to decide whether to 
undergo testing for a genetic disease for which a diag-
nosis might not have therapeutic consequences until 
adulthood. Treatments to slow disease progression in 
children with ADPKD are limited, and no clear evi-
dence exists to suggest that presymptomatic detec-
tion improves outcomes16. In addition, establishing 
a clinical or genetic diagnosis may have a substantial 
impact on the future ability of the child to secure insur-
ance policies or to gain access to certain professions. 
Considerations about insurance vary substantially by 
place of residence; in some countries, the results of 
genetic screening tests can legally be kept confidential, 
whereas in others a positive family history alone will 
affect insurability.
On the other hand, both the American and the Euro-
pean Society of Human Genetics consider presympto-
matic testing of minors for conditions with adult- onset 
acceptable if preventive actions can be initiated before 
adulthood17,18. Cohort studies in children with ADPKD 
show an elevated incidence of hypertension, proteinuria 
and left ventricular hypertrophy, which affect progno-
sis and are amenable to treatment19. Although these data 
are from tertiary referral centre populations and thus 
may be biased towards more severe cases, they demon-
strate that a subgroup of children exists in whom pre-
ventive treatment may be beneficial. Another potential 
advantage of early diagnosis is that the teenage years 
can provide a valuable opportunity to integrate lifestyle 
interventions such as a healthy, low- salt diet and ade-
quate fluid intake into the development of eating habits 
(discussed further below). The advent of treatment to 
slow disease progression and of pre- implantation genetic 
diagnosis have persuaded some clinicians to advocate 
screening for young adults20. For children, the situation 
is less clear as pharmacological studies in paediatric 
patients are ongoing and safe treatment options for chil-
dren with acceptable adverse effects and proven benefits 
have not yet been established.
Immediate or delayed screening
In our view, parents and young people may reasonably 
opt for either immediate diagnostic testing to confirm 
disease status or regular clinical screening to identify 
disease manifestations with the option of later diagnos-
tic testing. Regular clinical screening mainly comprises 
measurement of blood pressure and proteinuria, which 
should be performed at the same intervals as those 
recommended for children with proven symptomatic 
or asymptomatic disease (see below). The feasibility 
of regular blood pressure monitoring in the commu-
nity may vary in different settings and should be taken 
into account.
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Aggregate evidence quality Beneﬁt or harm predominates Beneﬁt and harm balanced
Level C
Single or few observational studies or multiple
studies with inconsistent ﬁndings or
major limitations
Level X
Exceptional situations where validating
studies cannot be performed and beneﬁt
or harm clearly predominates
Level B
Trials or diagnostic studies with minor
limitations; consistent ﬁndings from multiple
observational studies
Moderate 
recommendation
Moderate
recommendation
Level D
Expert opinion, case reports, reasoning from
ﬁrst principles
No recommendation may be madeWeak recommendation(based on low-quality evidence)
Level A
• Intervention: well-designed and conducted 
trials, meta-analyses on applicable populations
• Diagnosis: independent gold-standard 
studies of applicable populations
Strong 
recommendation
Strong recommendation
Weak recommendation
(based on balance of
beneﬁt and harm)
Fig. 1 | Matrix used for grading of evidence and assigning strength of recommendations. This matrix is currently 
used by the American Academy of Pediatrics12,13. Reproduced with permission from ref.13: Pediatrics 140, e20171904 
Copyright © 2017 by the AAP.
We recommend that parents receive non- directional 
counselling about the potential benefits and uncertain-
ties of current diagnostic screening tests. Health- care 
professionals should inform parents with the aim of 
shared decision- making and encourage them to keep 
the best interests of the child in mind. Teenagers and 
competent younger children should be involved in the 
decision- making process as much as possible, and ide-
ally a family approach will facilitate discussion to balance 
the views of the parents and the young person. We also 
encourage talking to children and adolescents about the 
possibility of disease transmission early on in an age- 
appropriate way as this positively influences coping and 
family interactions21–23. If discussion with the child is 
deferred until the formal age of majority, families may 
benefit from the help of a genetic counselling service or 
a similarly trained professional22.
Radiological diagnosis
Renal ultrasonography
The current gold standard for radiological diag-
nosis of ADPKD is renal ultrasonography (Box  2). 
Ultrasonography is an inexpensive and non- invasive 
method of examination that is particularly suitable for 
children because of their smaller body size and the fact 
that the procedure does not require sedation or ioniz-
ing radiation. Diagnostic ultrasonography criteria for 
ADPKD have been established only for adults24; however, 
in children, there is usually no clinical need to make a 
genetic diagnosis regardless of the ultrasonography find-
ings or to perform more sensitive diagnosis using MRI 
(which may require sedation) if the renal ultrasonogra-
phy scan is normal as cyst burden correlates with the risk 
of the main complications such as hypertension25. In line 
with clinical practice guidelines for adults26–28, we rec-
ommend reserving genetic testing to selected situations 
(see below). We have provided detailed guidance on the 
prenatal and postnatal imaging of single and multiple 
kidney cysts and their differential diagnosis in separate 
statements29,30.
Diagnostic specificity and sensitivity. In a PKD1 gene 
linkage analysis study, the diagnostic specificity of one 
or more cysts on ultrasonography in at- risk children was 
89% in those younger than 5 years of age and 100% in 
those older than 5 years of age31. Failure to confirm cysts 
on follow- up has been reported rarely with single but not 
with multiple cysts32–34 and may be due, for example, to a 
mistaken dilated calyx, mistaken prominent medullary 
pyramid or technical difficulties in obese children. For 
young adults, established imaging diagnostic criteria 
require at least three renal cysts on ultrasonography24,35 
or ten on MRI36. However, the studies on which these 
criteria are based did not include patients younger than 
15 years of age. Numerous studies have shown that, 
owing to the gradual appearance of cysts, children with 
ADPKD usually have a much lower number of cysts than 
adults, and young children may not yet have detectable 
cysts on ultrasonography, especially in families with a 
mild phenotype31–34,37–42. Diagnostic sensitivity is there-
fore better in older than in younger children and with 
the use of high- resolution versus lower- resolution ultra-
sonography. Parents should be counselled that the neg-
ative predictive value of a normal ultrasonography scan 
in childhood is limited and that later appearance of cysts 
may be due to a milder underlying genetic alteration 
(for example, PKD2 or GANAB (glucosidase- α neutral 
www.nature.com/nrneph
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Box 2 | radiological diagnosis
recommendation 2.1
ultrasonography is the current radiological method of 
choice to screen for autosomal dominant polycystic 
kidney disease (aDPKD) in children (evidence level B; 
recommendation level moderate).
recommendation 2.2
in a child under 15 years with a positive family history of 
aDPKD, sonographic detection of one or more kidney 
cysts is highly suggestive of aDPKD (evidence level B, 
recommendation level moderate). in a fetus or neonate 
with a positive family history of aDPKD, hyperechogenic 
and/or enlarged kidneys (>2 s.d.) on ultrasonography are 
suggestive of aDPKD (evidence level C; recommendation 
level moderate).
recommendation 2.3
if kidney ultrasonography is normal in an at- risk child, 
this finding does not exclude aDPKD. However, if making 
a diagnosis based on ultrasonography is requested, it is 
not necessary to rescreen at intervals shorter than 3 
years (evidence level C; recommendation level 
moderate).
recommendation 2.4
Multiple cysts with negative family history require 
clinical work- up for cystic kidney diseases (evidence level 
B, recommendation level moderate).
recommendation 2.5
Detection of a solitary cyst in childhood requires follow- 
up imaging (evidence level C; recommendation level 
moderate).
recommendation 2.6
there are no established Mri- based diagnostic criteria 
for aDPKD in children younger than 15 years (evidence 
level B–C; recommendation level moderate).
Box 1 | Screening in at- risk minors
recommendation 1.1
all parents of at- risk minors should be counselled about inheritance of autosomal 
dominant polycystic kidney disease (aDPKD) and the potential benefits and harms of 
diagnostic screening (evidence level X; recommendation level strong).
recommendation 1.2
Parents of at- risk minors should be offered access to diagnostic screening after 
counselling (evidence level X; recommendation level moderate).
recommendation 1.3
For asymptomatic minors at risk of aDPKD, repeated screening for treatable, but 
usually asymptomatic disease manifestations (that is, hypertension and proteinuria) 
without diagnostic testing or immediate diagnostic screening (by ultrasonography or 
genetic testing) should be considered equally valid approaches to clinical care. the 
decision whether to perform diagnostic screening should be shared between parents 
(or legal guardians) and health- care professionals. Minors should be involved where 
possible (evidence level X; recommendation level moderate).
recommendation 1.4
if the decision is taken not to perform diagnostic screening in childhood, parents should 
be made aware of their responsibility to inform their children of disease risk when they 
reach legal age of majority (evidence level X, recommendation level moderate).
AB form) mutations) or variability of the individual clin-
ical course37. As cysts develop slowly and children with 
fewer cysts have later onset of hypertension and protein-
uria25,43–45, children with a normal ultrasonography scan 
should not be subjected to frequent repeat scans.
Multiple cysts. The incidence of simple cysts in children 
is very low46. Multiple kidney cysts in childhood are 
therefore highly suggestive of ADPKD or another cystic 
nephropathy (such as cystic dysplasia or multicystic- 
dysplastic kidney) and should be investigated. Clinical 
work- up will include inquiry about (related) symptoms, 
detailed history and physical examination and may 
require further investigations of other organ systems. 
Parental examination may reveal previously undetected 
ADPKD47.
Solitary cysts. In children with a positive family history, 
a solitary cyst is a very likely sign of ADPKD, but in rare 
cases the cyst may not be confirmed on follow- up32–34. In 
children with a negative family history, ultrasonography 
of the parents should be performed and, if the results 
are normal, further work- up or follow- up of the child 
is needed to exclude the appearance of multiple cysts or 
the development of a complex cyst.
MRI
In adults and probably also teenage children, MRI is 
more sensitive than ultrasonography for detection of 
kidney cysts in ADPKD36,43,48. In neonates and infants, 
high- resolution ultrasonography can detect even small 
cysts, but no studies have defined a gold standard for 
imaging kidney cysts in this age group. As MRI usually 
requires sedation in children younger than 6 years and is 
more expensive than ultrasonography imaging, it is not 
the diagnostic method of choice for paediatric ADPKD.
Molecular diagnosis
In adults, genetic testing for ADPKD is usually not done 
because of the clearly established imaging diagnostic cri-
teria and the technical challenges of sequencing PKD1. 
However, knowledge about genotype–phenotype corre-
lations is increasing, as is the need for more accurate 
estimation of prognosis in view of novel therapies49.
Both very- early-onset ADPKD and rapidly progres-
sive disease may be due to unusual genetic constellations, 
such as biallelic mutations (homozygous, compound 
heterozygous or digenic) with at least one weak PKD1 
or PKD2 hypomorphic allele5,50–52. Combinations of an 
ADPKD allele with an allele of another cystic nephrop-
athy such as TSC2 (for example, as a contiguous gene 
deletion syndrome (CGS)) may also radically alter the 
renal disease phenotype53. HNF1B mutations can mimic 
ADPKD with important consequences for prognosis, 
the likelihood of comorbidities (for example, congenital 
hepatic fibrosis in PKHD1 or maturity onset diabetes 
of the young type 5 (MODY5) in HNF1B) and the risk 
of disease in siblings54. Where available, simultaneous 
analysis of a panel of polycystic kidney disease genes 
is recommended for children with very- early-onset 
disease independent of their family history or rapidly 
progressive cystic kidney disease and negative family 
history (Box 3). An unusually severe clinical course with 
a positive family history may also be a sign of an unu-
sual genetic constellation, but the likelihood is much 
lower than in the aforementioned cases. Patients with 
incidental finding of a single cyst and no extrarenal fea-
tures should primarily receive clinical work- up and be 
followed up by imaging. Genetic testing is unlikely to 
reveal a monogenic cause or change management.
We currently recommend next- generation sequenc-
ing panel examination rather than testing single ADPKD 
genes because of the large phenotypic overlap between 
different cystic kidney diseases and large genetic heter-
ogeneity54. A cystic kidney disease panel should include 
adequate coverage of PKD1, PKD2, PKHD1, Daz- 
interacting zinc- finger protein 1-like (DZIP1L), HNF1B 
and genes for other ciliopathies such as nephronophthisis 
(NPHP) and Bardet–Biedl syndrome (BBS).
Hypertension
Hypertension is one of the most common complications 
of ADPKD in childhood. A systematic review by Marlais 
et al. that included >900 children with ADPKD from 
14 studies reported that the prevalence of hypertension 
was 20% (95% CI 15–27%); this prevalence was shown 
to increase with age in a meta- regression analysis19. This 
finding might be influenced by tertiary centre referral 
bias because the clinical experience with adult patients 
suggests that hypertension frequently becomes apparent 
later in life. The average age of onset of hypertension in 
adults with ADPKD is 30–34 years55 and precedes loss of 
renal function. A study from large centres that included 
children and adults confirmed a risk of hypertension 
of approximately 20% for those younger than 19 years 
Nature reviews | Nephrology
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Box 3 | Molecular diagnosis
recommendation 3.1
we recommend offering genetic testing for cystic kidney 
disease genes to infants and children with very-early- 
onset (veO) symptomatic disease independent of 
family history and to those with progressive disease 
(increasing cyst number or kidney volume) and a negative 
family history (evidence level B; recommendation 
level moderate).
recommendation 3.2
in patients with a positive family history and unusually 
severe clinical course, genetic testing may be beneficial 
(evidence level D; recommendation level weak).
recommendation 3.3
we do not recommend genetic testing in patients with a 
single cyst, no extrarenal findings and a negative family 
history of autosomal dominant polycystic kidney disease 
(aDPKD) (evidence level B–C; recommendation level 
moderate).
recommendation 3.4
For genetic testing in children with veO polycystic 
kidney disease or unusually progressive disease with a 
negative family history, we suggest using a multigene 
panel, including cystic kidney disease genes with a 
protocol adequately covering PKD1 rather than testing 
single aDPKD genes (evidence level C; recommendation 
level weak).
of age, which is significantly higher than that of this age 
group in the healthy population (<2%)56. Elevated blood 
pressure is significantly associated with kidney volume 
and cyst score in children with ADPKD25,43–45,57.
Blood pressure measurement
As hypertension is the main treatable disease manifesta-
tion of ADPKD in childhood, we recommend adhering 
to the stringent yearly monitoring intervals for clinic 
blood pressure measurements recommended by the 
AAP and the European Society of Hypertension (ESH) 
for otherwise healthy children13 (Box 4). This recommen-
dation also applies to at- risk children of affected parents 
who have chosen to defer diagnostic testing.
Ambulatory blood pressure monitoring (ABPM) is 
more reproducible and accurate than clinic blood pres-
sure measurement58, and ABPM values associate more 
closely with left ventricular hypertrophy in children59 
and with renal disease progression or death in adults 
with chronic kidney disease (CKD)60 than do clinic blood 
pressure values. A substantial proportion of children 
with CKD have masked hypertension61, justifying the 
routine use of ABPM for high- risk children13. In addi-
tion, ABPM can exclude white coat hypertension and 
help to avoid unnecessary treatment62. ABPM becomes 
more useful as children age because measurements are 
less well tolerated by younger children, who also have 
a lower prevalence of hypertension19, and reliable ref-
erence values are available only for individuals with a 
height of ≥120 cm. Isolated night- time hypertension with 
normal daytime blood pressure, which can be picked up 
only on ABPM, has been reported in 16–18% of children 
with ADPKD25,57. This finding underlines the usefulness 
of ABPM in this patient group. Monitoring intervals will 
depend on local availability, level of clinic blood pressure 
and/or the use of antihypertensive medication.
Home blood pressure measurements are less suita-
ble than repeated clinic or ABPMs for initial diagnosis 
of hypertension owing to the current lack of definitive 
paediatric reference values13. However, home measure-
ments can be useful to assess changes over time, moni-
tor treatment and increase compliance, thus helping to 
reduce the frequency of more costly ABPM63,64. The use 
of home blood pressure measurement will depend on 
the compliance of the family and the child, as well as 
the availability of monitors that have been specifically 
validated for children.
Antihypertensive treatment
Blood pressure thresholds. No studies on blood pressure 
thresholds for antihypertensive treatment in paediatric 
hypertension have been published. Owing to the high 
cardiovascular mortality of patients with childhood- onset 
CKD65 and the beneficial effect of lowering blood pres-
sure on progression of renal disease66, we support the low 
antihypertensive treatment threshold (ninetieth percen-
tile for age, sex and height, which equals 130/85 mmHg 
on clinic measurements for those ≥16 years of age) that is 
recommended for children with CKD by Kidney Disease: 
Improving Global Outcomes (KDIGO)67.
Blood pressure targets. A randomized controlled trial 
(RCT) of antihypertensive therapy in children with CKD 
stage 2–4 showed a significant beneficial effect on renal 
survival when treatment was targeted to reduce 24-hour 
mean arterial pressure to below the fiftieth percentile 
on ABPM66. However, a post hoc analysis reported no 
further benefit for an achieved blood pressure below 
the seventy- fifth percentile66. The HALT- PKD Study 
A demonstrated a significant benefit of a lower blood 
pressure goal (95/60 to 110/75 mmHg) versus a stand-
ard blood pressure target (120/70 to 130/80 mmHg) in 
terms of total kidney volume (TKV), left ventricular mass 
index (LVMI) and albuminuria in adults with ADPKD 
and stage 1–2 CKD68. However, a smaller randomized 
trial of intensive blood pressure control in children with 
ADPKD did not reach statistical significance69. Thus, the 
long- term benefits of lower blood pressure need to be bal-
anced against the need for more medications and higher 
risk of adverse effects in the short term. We consider the 
KDIGO and ESH blood pressure target for children with 
CKD (less than the seventy- fifth percentile) to be more 
evidence- based for use in children with ADPKD than 
the stricter AAP target (less than the fiftieth percentile).
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Box 4 | hypertension
recommendation 4.1
all children at risk of or diagnosed with autosomal dominant polycystic kidney disease 
(aDPKD) should have their blood pressure measured at least once a year (that is, at the 
same interval as healthy children) (evidence level C; recommendation level moderate).
recommendation 4.2
twenty- four-hour blood pressure on ambulatory blood pressure monitoring (aBPM) is 
the preferred method for defining hypertension in children aged 5 years and older 
(evidence level C; recommendation level moderate).
recommendation 4.3
in children with confirmed aDPKD, aBPM should be performed at least once from age 
5 years (evidence level B; recommendation level moderate).
recommendation 4.4
For children with aDPKD on antihypertensive medication, we suggest monitoring 
blood pressure control by regular home blood pressure measurements (evidence level 
C; recommendation level weak).
recommendation 4.5
we suggest that children with aDPKD receive antihypertensive treatment if their blood 
pressure repeatedly exceeds the ninetieth percentile or is >130/85 mmHg if age  
>16 years (evidence level D; recommendation level moderate).
recommendation 4.6
For treatment of hypertensive children with aDPKD, we suggest a target blood 
pressure below the seventy- fifth percentile or <125/72 mmHg if age >16 years 
(evidence level C; recommendation level moderate).
recommendation 4.7
Lowering blood pressure below the fiftieth percentile or <120/70 mmHg if age >16 years 
may provide additional long- term benefit for hypertensive children with aDPKD 
(evidence level D; recommendation level weak).
recommendation 4.8
we recommend using angiotensin- converting enzyme (aCe) inhibitors or angiotensin 
receptor blockers as first- line antihypertensive treatment in children with aDPKD who 
have hypertension and albuminuria (evidence level B; recommendation level 
moderate).
recommendation 4.9
we suggest using aCe inhibitors or angiotensin receptor blockers as first- line 
antihypertensive treatment in children with aDPKD who have hypertension without 
albuminuria (evidence level C; recommendation level moderate).
First- line treatment. Compared with other antihyper-
tensive agents, angiotensin- converting enzyme (ACE) 
inhibitors and angiotensin receptor blockers (ARBs) 
have the largest evidence base for efficacy and safety 
in paediatric patients and in patients with renal hyper-
tension. In patients with proteinuria, the superiority of 
ACE inhibitors and ARBs over other antihypertensive 
drug classes has been clearly demonstrated70. Whether 
renin–angiotensin–aldosterone system (RAAS) inhibi-
tors have superior efficacy to β- blockers or calcium chan-
nel blockers in adults with ADPKD is less clear71–74. Dual 
RAAS blockade does not seem to have additional benefit 
on disease progression over that of improved blood pres-
sure control compared with an ACE inhibitor or ARB 
alone in adults with early or late ADPKD68,75. Diuretics 
should be used with caution as they may increase vas-
opressin levels and seem to have deleterious effects on 
estimated GFR (eGFR) in comparison to ACE inhibi-
tors in ADPKD76. In an animal model of ADPKD, cal-
cium channel blockers promoted cyst growth77, but the 
findings of human studies are inconsistent73,78,79.
Proteinuria
As mentioned above, the incidence of proteinuria is 
increased in children with ADPKD. In the systematic 
review by Marlais et al., the prevalence of proteinuria in 
these children was 20% (96% CI 9–40%)19; however, this 
finding may also be influenced by tertiary centre bias. 
Proteinuria does not seem to be associated with hyper-
tension but is one of the most established risk factors for 
progression of CKD in adults and children regardless 
of the cause of CKD80–85. Owing to its therapeutic and 
prognostic relevance, monitoring of proteinuria and/or 
albuminuria should be considered standard care for 
children with ADPKD (Box 5).
Proteinuria can be considered not only as a marker 
of CKD but also as a cause of further tubulointerstitial 
damage and fibrosis, as well as glomerular hypertrophy86. 
Reduction of proteinuria using ACE inhibitors or ARBs 
is associated with significant improvement in renal sur-
vival in patients with CKD87, although RCTs in children 
are lacking. Control of proteinuria is therefore an impor-
tant aspect of current treatment recommendations for 
CKD67. In children with ADPKD who have protein uria, 
ACE inhibitors or ARBs should be used as the primary 
treatment as in other chronic kidney diseases.
Albuminuria tends to be mild in adults with ADPKD; 
for example, in the TEMPO 3:4 study, the median 
albumin/creatinine ratio (ACR) was 3.2 mg/mmol. Of 
all patients, 49% of patients had moderate albuminuria 
(ACR ≥3 mg/mmol) and just 3.4% had severe albuminu-
ria (ACR ≥30 mg/mmol)88. We therefore recommend 
measuring ACR in a laboratory rather than perform-
ing dipstick testing, which is a less sensitive and specific 
method.
Routine monitoring of cyst growth
In asymptomatic children, routine monitoring of cyst 
growth should not be performed too frequently as ultra-
sonography findings are very unlikely to influence clini-
cal management decisions and the psychological burden 
of regular ‘cyst counting’ should be considered. Cyst 
number and TKV correlate with hypertension25,43–45, but 
ultrasonography cannot replace direct measurement of 
blood pressure, which remains essential in clinical prac-
tice. Although children with very- early-onset ADPKD 
have poorer outcomes89, no studies have examined 
whether the prediction of ‘rapid progressors’ by repeated 
imaging in children is feasible and clinically helpful. Our 
recommendation (Box 6) would change in the future if 
paediatric studies show a predictive value of kidney 
imaging on later progression to end- stage renal disease 
(ESRD; as has been shown in adults90) and a treatment 
to slow disease progression is licensed specifically for 
children who are at risk of early progression to ESRD.
As discussed below, ultrasonography examination 
is an essential tool in the investigation of symptomatic 
children, for example, when investigating urinary tract 
infections (UTIs), cyst haemorrhage, gross haema-
turia, renal stones or cyst infections. Before transition 
from paediatric to adult care, ultrasonography findings 
may also provide some guidance as to whether to refer 
the patient to a general practitioner or directly to a 
nephrologist.
Monitoring progression in ADPKD trials
Patient and renal survival are the most meaningful 
long- term outcomes in ADPKD trials but are difficult 
to assess in paediatric populations. GFR is nearly always 
within the normal range during childhood ADPKD19,33, 
thus eGFR decline is a suitable marker of disease pro-
gression only in the small subgroup of children with very 
advanced ADPKD89. Height- adjusted TKV (htTKV) on 
MRI is the most established imaging surrogate parame-
ter for monitoring disease progression in adult ADPKD 
trials91. To date, only one study has investigated the cor-
relation of MRI measurements with disease severity in 
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Box 5 | proteinuria
recommendation 5.1
Children with autosomal dominant polycystic  
kidney disease (aDPKD) and those at risk of aDPKD 
should be monitored for albuminuria (evidence level C; 
recommendation level weak).
recommendation 5.2
if proteinuria is present, angiotensin- converting 
enzyme inhibitors or angiotensin receptor blockers 
should be used as primary treatment as in other chronic 
kidney diseases (evidence level C; recommendation 
level moderate).
Box 6 | routine monitoring of cyst growth
recommendation 6.1
in asymptomatic children with autosomal dominant 
polycystic kidney disease (aDPKD), the clinical value  
of repeated ultrasonography is unclear. Depending  
on the clinical course and the age of the patient, 
ultrasonography may provide insights into the dynamics 
of disease progression but, in routine clinical care of 
classical aDPKD, we suggest that monitoring intervals 
shorter than 3 years are unnecessary (evidence level X, 
recommendation level weak).
children with ADPKD. This study found a correlation of 
MRI cyst volume and TKV with current hyper tension 
status, as well as a predictive value of cyst volume for 
the development of hypertension43. In contrast to adults, 
kidneys in children with early ADPKD can usually be 
imaged within one ultrasonography viewing field (max-
imum dimension ~17 cm), which enables adequate 
measurements for volume calculation using the ellipsoid 
formula92. However, quantification of cyst number in 
older children is probably more accurate with MRI once 
multiple small cysts become too numerous for count-
ing on ultrasonography. For TKV, MRI measurements 
seem to be slightly larger than ultrasonography meas-
urements in children with ADPKD, with discrepancies 
mainly for larger kidneys43,48. Correlation of hyper-
tension to kidney volume on renal ultrasonography has 
been demonstrated in three paediatric studies25,44,45. 3D 
ultrasonography is a promising new tool for TKV meas-
urements in children but requires further validation48. 
As non- cooperative children require sedation for MRI, 
use of this approach does not seem to be warranted in 
a research setting without direct benefit for the child 
(Box 7). Use of MRI planimetry to measure TKV may be 
appropriate for adolescents in clinical trials or children 
with very large kidneys.
Lifestyle interventions and treatments
Maintenance of normal weight
No RCTs of lifestyle interventions with relevant outcome 
measures have been conducted in patients with ADPKD. 
However, there is no evidence to suggest that lifestyle rec-
ommendations for the general paediatric population, as 
well as those for children and adults with CKD, do not 
apply to children with ADPKD (Box 8). The importance 
of maintaining normal weight is underlined by the obser-
vation that obesity is an independent predictor of faster 
loss of renal function in adults with early ADPKD93.
Salt intake
The dietary salt intake of the general population of 
infants, toddlers and older children on a Western diet 
far exceeds the recommended amounts94. In adults with 
CKD, high salt intake is associated with higher blood 
pressure, proteinuria and progression to ESRD95–98. 
Higher sodium intake also blunts the antihyperten-
sive and antiproteinuric effects of RAAS blockade99,100. 
In patients with ADPKD, urinary sodium excretion cor-
relates with kidney growth98,101. Moreover, in patients 
with later- stage ADPKD, higher urinary sodium levels 
(a surrogate for sodium intake) increased the risk of a 
composite end point of a 50% reduction in eGFR, ESRD 
or death98. Few interventional trials exist, but restrict-
ing salt intake lowers blood pressure and proteinuria 
in adults with ADPKD or CKD102,103. In accordance 
with numerous guidelines for CKD, we recommend 
that children with ADPKD should aim to achieve the 
recommended intake for healthy children, which may 
require extra assistance (for example, advice from a 
dietician).
Water and protein intake
High water intake to suppress endogenous vasopressin 
production is often recommended for patients with 
ADPKD26,27. However, evidence from interventional 
and observational studies does not confirm a benefit 
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Box 7 | Monitoring progression in ADpKD trials
recommendation 7.1
Clinical trials in children with autosomal dominant 
polycystic kidney disease (aDPKD) should monitor 
hypertension, proteinuria, kidney volume, cyst volume 
(or number) and (estimated) glomerular filtration rate 
(evidence level X; recommendation level moderate).
recommendation 7.2
For kidney volume measurements in clinical trials, total 
kidney volume determined by Mri is recommended to 
monitor progression in cooperative children. 
ultrasonography monitoring of kidney size and cyst 
number is preferable to Mri in non- cooperative children 
(evidence level X; recommendation level moderate).
Box 8 | lifestyle interventions and treatmentsa
recommendation 8.1
a healthy lifestyle including physical activity and 
maintenance of normal weight should be promoted in all 
patients with autosomal dominant polycystic kidney 
disease (aDPKD) (evidence level B–C; recommendation 
level moderate).
recommendation 8.2
Children with aDPKD should be encouraged to achieve 
the recommended low dietary salt intake (evidence level 
B; recommendation level moderate).
recommendation 8.3
High water intake and avoidance of excessive protein 
intake may be beneficial in slowing progression of 
renal failure in children with ADPKD (evidence level D; 
recommendation level weak).
recommendation 8.4
use vasopressin analogues (for example, desmopressin) 
with caution in children and young people with 
ADPKD and enuresis due to potential negative effects 
on cyst growth (evidence level X, recommendation 
level moderate).
recommendation 8.5
Do not routinely offer vasopressin antagonists to 
children and young people with aDPKD. Off- label use of 
vasopressin antagonists can be considered at clinician 
discretion in children at high risk of early progression 
based on large total kidney volume, rapid kidney growth, 
family history, etc. (evidence level D, recommendation 
level weak).
recommendation 8.6
mtOr inhibitors should not be used in children and 
adolescents with classical aDPKD (evidence level B, 
recommendation level moderate).
recommendation 8.7
there is insufficient evidence from adult studies 
supporting the use of somatostatin analogues in aDPKD. 
they should not be used in children with aDPKD 
(evidence level C, recommendation level moderate).
aNo consensus could be reached on the use of statins to slow 
disease progression in children with aDPKD.
of this intervention104, and a randomized trial is still 
ongoing105. Studies suggest that adults with ADPKD are 
more sensitive to water deprivation than those with IgA 
nephro pathy and produce higher levels of endo genous 
vasopressin to reach similar levels of urine osmo lality 
to those of healthy individuals106,107. Dehydration should 
therefore be avoided, and patients should be encour-
aged to drink to satisfy thirst108. A low- osmolar diet 
(low sodium, low protein and adjusted water intake 
to decrease urinary osmolality to <280 mOsM/kg 
(280 mmol/kg)) decreased the levels of endogenous 
copeptin (a surrogate marker of vasopressin) in a short 
study of adults with ADPKD, but a potential long- term 
benefit on cyst growth remains speculative109. In chil-
dren with non- ADPKD CKD, an RCT did not find a 
beneficial effect of a low- protein diet on GFR decline110. 
Unnecessary protein restriction should be avoided in 
children to reduce the risk of malnutrition.
Vasopressin analogues
Vasopressin analogues are one of several treatment 
options for nocturnal enuresis in school- age children111. 
A 1994 study reported a significant increase in urinary 
frequency and a decrease in urinary concentrating ability 
in children with severe ADPKD (more than ten cysts)33. 
By contrast, children with ten or fewer cysts had a non-
significantly increased self- reported urinary frequency 
and no decrease in concentrating ability compared with 
children of parents with ADPKD who did not have any 
cysts on ultrasonography. A study that included 16 chil-
dren who were diagnosed with ADPKD because of their 
symptoms found that only 1 of these children presented 
with enuresis16; this frequency is probably similar to 
that of the general paediatric population. As vasopres-
sin antagonists reduce the rate of cyst growth and eGFR 
loss in patients with ADPKD112,113, vasopressin analogues 
can reasonably be considered to be detrimental in these 
patients; therefore, it seems wise to prefer other treat-
ment options for the management of nocturnal enuresis 
in children with ADPKD111.
Statins
In a prospective, double- blind RCT in 110 children and 
young adults aged 8–22 years with ADPKD and good 
renal function, the addition of pravastatin to lisinopril 
(with target blood pressure in the fiftieth to seventy- fifth 
percentile) resulted in a significantly slower increase in 
htTKV than placebo114. As expected, eGFR did not differ 
between the groups. Although LDL and total cholesterol 
levels did not correlate directly with clinical outcome 
variables (htTKV, albuminuria and LVMI), the statin- 
induced change in urinary biomarkers of endothelial 
dysfunction was associated with prospective change 
in htTKV115. Routine statin treatment for cardiovas-
cular indications is more prevalent in adults than in 
children. A secondary analysis of the HALT- PKD trials 
reported no effect of self- reported statin use versus no 
statin use on TKV or composite end points in adults 
with ADPKD116. Therefore, the encouraging findings 
in the only controlled paediatric study of statin therapy in 
ADPKD published to date need to be balanced against 
the lack of evidence of beneficial effects on renal outcome 
in the uncontrolled adult study116 and the lack of regu-
latory approval of statins for ADPKD. A controlled trial 
in adults is ongoing117. Paediatric safety data for statins 
in large cohorts have been published only for children 
with familial hypercholesteremia118–121, and the risk of 
statin therapy in pregnancy is unclear122. We were there-
fore unable to reach a consensus on the use of statins 
to slow disease progression in children with ADPKD.
Vasopressin antagonists
Tolvaptan has been licensed to delay disease progression 
in adults with ADPKD who are likely to go on to develop 
ESRD112,113 and has also been shown to reduce ADPKD- 
related pain123. Currently, no direct data exist to support 
the use of vasopressin antagonists in children and ado-
lescents with ADPKD, and no safety studies in this group 
have been published. However, a multinational, double- 
blind, placebo- controlled trial of tolvaptan in teenagers 
with ADPKD is currently underway124. Although early 
initiation of treatment resulting in a longer lifetime treat-
ment period may theoretically lead to a greater absolute 
prevention of eGFR loss than that achieved with later 
treatment initiation125, the medium- term protection 
against relative eGFR loss is much lower in patients 
with preserved renal function than in those with more 
advanced CKD. Tolvaptan is known to cause occasional 
hepatic injury in adult ADPKD126, but the impact of this 
agent on liver enzymes in children is not yet known. In 
addition, treatment with vasopressin antagonists causes 
substantial polyuria, which is likely to affect sleep and 
daily activities and thus may influence quality of life. 
Patients are likely to require additional counselling 
and support to successfully adhere to such a disruptive 
treatment during adolescence.
mTOR inhibitors
Prospective RCTs did not find an eGFR benefit of mTOR 
inhibitors in adults with ADPKD, and these agents were 
associated with important adverse effects such as wors-
ening proteinuria, hyperlipidaemia and cytopenias127–129. 
We therefore recommend that mTOR inhibitors should 
not be used in children and adolescents with classical 
ADPKD.
In patients with PKD1/TSC2 CGS, mTOR inhibi-
tors are potentially beneficial as renal cysts have been 
reported to decrease in children with tuberous scle-
rosis receiving treatment with mTOR inhibitors for 
other indications130. However, as cyst volume does not 
automatically equate to GFR benefit127 and there is no 
published experience of these drugs in PKD1/TSC2 
CGS, they should be reserved for the licensed indica-
tions of subependymal giant cell astrocytoma and large 
angiomyolipomas.
Somatostatin analogues
Use of somatostatin analogues to delay disease progres-
sion in ADPKD has been studied only in adults. RCTs 
indicate that these agents are beneficial in patients with 
severe liver disease but do not have a sustained beneficial 
effect on renal function131–135. No severe cases of ADPKD- 
related liver disease in children have been reported in 
the literature, and paediatric experience with these drugs 
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is limited. We therefore recommend that somatostatin 
analogues should not be used in children with ADPKD.
Management of complications
Abdominal pain
Abdominal pain is reported in 10–20% of children with 
ADPKD16,33,136. As abdominal and back pain are very 
common symptoms among children and adolescents 
in general, further investigations and treatment need to 
be guided by acuity, intensity and associated findings137 
(Box 9). Even in the early stages of ADPKD, episodes of 
nonspecific abdominal pain are frequently reported by 
adults and tend to be underestimated by physicians138. 
However, patients might have a biased perception of 
pain, especially if investigations for abdominal pain 
led to their incidental diagnosis of ADPKD. Chronic 
pain requires a multidisciplinary approach to avoid 
overtreatment or undertreatment and to improve 
self- management139. Chronic and/or high- dose use 
of nonsteroidal anti- inflammatory agents (NSAIDs) 
should be avoided because of potential renal adverse 
effects140,141.
Urinary tract and cyst infections
Cohort studies suggest an increased incidence of UTIs 
in children with ADPKD (up to 15–25%)6,16,33,37,136. 
These studies may be biased as imaging for UTI may 
have prompted the diagnosis of ADPKD. As no studies 
have suggested an increased incidence of complicated 
or prolonged infections in children with ADPKD, local 
standards for the diagnosis and treatment of UTI in 
otherwise healthy children should be applied.
Suspicion of upper UTI in children with ADPKD 
should lead to examination of urine (and blood) cul-
tures, as well as renal ultrasonography, much the same as 
in otherwise healthy children142. Cyst infection is a very 
rare complication of childhood ADPKD. If suspected 
clinically or on ultrasonography imaging, experience 
in adults suggests that 18F- FDG–PET/computed 
tomography (CT) is superior to contrast CT or MRI to 
confirm the diagnosis and localize the infected cyst, but 
this approach can produce false- negative results143,144. 
Treatment of cyst infection has a high failure rate 
and requires long- term use of antibiotics145. Precise 
localization of an infected cyst can be extremely dif-
ficult in patients with many cysts but is necessary 
only for refractory infection when cyst drainage may 
be required.
Haematuria and cyst haemorrhage
Macroscopic haematuria is reported in 5–15% of chil-
dren with ADPKD6,16,33,37,45,136,146. However, studies may 
overestimate the incidence, as imaging for haematuria 
may have prompted the diagnosis. Macroscopic haema-
turia is associated with enlarged TKV in adults147 but 
was not more common in children with severe versus 
moderate versus no cysts33, nor in children with very- 
early-onset disease versus those with later onset146. Gross 
haematuria before the age of 30–35 years is associated 
with worse renal survival in adults with ADPKD148,149. 
Observations in adults with severe cyst haemorrhage 
seem to suggest a benefit of treatment with tranexamic 
acid150,151, but the efficacy of this therapy has not been 
investigated in children.
Nephrolithiasis
Nephrolithiasis is an exceedingly rare complication in 
children with ADPKD, and ultrasonography should be 
used as the first- line imaging modality to rule out stones 
or other urinary tract obstructions. If kidney stones are 
found, additional risk factors for stone disease should be 
investigated, and a high fluid intake and symptomatic 
treatment are recommended.
Liver cysts
As the size and number of ADPKD- related liver cysts 
are known to increase in pregnancy, avoidance of exog-
enous oestrogens and hormone replacement therapy is 
generally recommended for women with ADPKD152. 
However, the prevalence of hepatic cysts in chil-
dren with ADPKD is <5%, with no reports of severe 
cases6,16,33,136,146,153. The risk of future aggravated liver dis-
ease in young women with ADPKD considering hormo-
nal contraceptive therapy should be balanced against the 
risk of unplanned pregnancy. Assessment of the burden 
of liver cysts and family history might assist in clinical 
decision- making.
Screening for extrarenal complications
Mitral valve prolapse
A systematic study published in 1995 reported mitral 
valve prolapse in 12% of children with ADPKD154. 
This prevalence was significantly higher than that 
of their healthy siblings (3%) but is within the range 
reported  for healthy children and is lower than 
that reported for adults with ADPKD (25%)155–157. As 
children without a murmur are unlikely to have hae-
modynamically relevant mitral valve prolapse, they do 
not require echocardiographic screening for mitral valve 
prolapse (Box 10).
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Box 9 | Management of complications
recommendation 9.1
Children with autosomal dominant polycystic kidney disease (aDPKD) presenting with 
abdominal pain should receive normal work- up also considering other causes of pain 
(evidence level D, recommendation level weak).
recommendation 9.2
Diagnosis and treatment of lower urinary tract infection in children with aDPKD 
should be the same as in otherwise healthy children (evidence level D, recommendation 
level weak).
recommendation 9.3
in a child with aDPKD and fever, pyelonephritis and cyst infection should be 
considered. Kidney ultrasonography is the first imaging modality to investigate the 
aetiology (evidence level D, recommendation level weak).
recommendation 9.4
in a child with aDPKD and gross haematuria, cyst haemorrhage and nephrolithiasis 
should be considered. Kidney ultrasonography is the first imaging modality to 
investigate the aetiology (evidence level D, recommendation level weak).
recommendation 9.5
all young women with aDPKD considering contraceptive therapy should receive 
counselling on potential aggravation of polycystic liver disease with exogenous 
oestrogen exposure (evidence level D, recommendation level weak).
Intracranial aneurysm
In adults with ADPKD, screening for intracranial aneu-
rysms is generally recommended only if additional risk 
factors are present such as a positive family history, 
previous intracranial aneurysms or a high- risk pro-
fession26,27,158,159. However, some authors disagree with 
this recommendation, arguing that screening is cost- 
effective160. Treatment strategies for unruptured intrac-
ranial aneurysms are still controversial. As rupture of 
intracranial aneurysm is an exceedingly rare complica-
tion in childhood161, routine screening is not justified. 
In rare cases with a positive family history and a strong 
desire to ease anxiety by screening, an individualized 
approach is justified.
Liver cysts
No reports exist of clinically relevant complications 
of ADPKD- related liver cysts in children6,16,33,37,146,153. 
Congenital hepatic fibrosis is not a feature of classical 
ADPKD. Ultrasonography of the liver may be a reason-
able investigation at first presentation of children with 
suspected ADPKD if alternative diagnoses are being 
considered or in the case of acute abdominal pain. 
However, we do not recommend regular screening for 
liver cysts in children with confirmed ADPKD.
Referral to specialized centres
Newborn babies and infants with severe cystic disease 
comprise a heterogeneous group who pose numerous 
challenges to diagnosis and management. Extended 
genetic testing of these patients is recommended to 
inform genetic and prognostic counselling in a special-
ized centre. However, neonates or fetuses with hyper-
echogenic kidneys and a family history of ADPKD who 
do not have symptoms or enlarged kidneys should not 
be considered to have severe disease. Children with 
TSC2/PKD1 CGS typically have severe polycystic kidney 
disease and may reach ESRD in young adulthood162,163. 
We recommend referral to a specialized centre and 
multidisciplinary care for these patients.
Psychosocial aspects
The consensus group shares the view of a current 
multidisciplinary position statement on ADPKD that 
emphasizes the need for “a holistic and comprehensive 
assessment of the manifestations, complications, prog-
nosis and impact of the disease (in physical, psychologi-
cal and social terms) on the patient and their family”164. 
Although young adults with ADPKD usually carry a 
much lower burden of physical impairment than older 
patients, they have to make lifestyle, career and family 
planning choices that will have lifelong effects. Studies in 
families with ADPKD have shown a high psychological 
burden of both ‘genetic guilt’ and anxiety about future 
health problems.
We recommend that families of children with ADPKD 
should be encouraged to discuss the risk of disease trans-
mission with their children (Box 11). Parents affected by 
inheritable disease often find communication with their 
children difficult and desire professional assistance, 
including developmentally appropriate disease informa-
tion and advice on managing their children’s emotional 
reactions21. Qualitative studies show that avoiding such 
discussions can be a source of family tensions through 
misunderstanding, blame and secrecy23, whereas open 
communication with younger children promotes effec-
tive coping strategies and makes families more resilient23. 
Multi- family discussion groups can be a valuable tool for 
promoting such intrafamilial discussions165.
Several lifestyle interventions can be recommended 
for patients with ADPKD (see above), irrespective of 
their CKD stage. As teenage and young- adult years 
provide the unique opportunity to establish healthy 
living habits without having to break previous habits, 
this period is an important age for counselling. Relevant 
messages include the importance of a healthy, low- salt 
diet, adequate fluid intake, regular physical exercise, 
avoiding obesity, abstention from smoking and avoid-
ance of nephrotoxic medication. Young women should 
also be counselled to avoid high- oestrogen-containing 
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Box 10 | Screening for extrarenal complications
recommendation 10.1
in children with autosomal dominant polycystic kidney disease (aDPKD) without a 
heart murmur, screening for mitral valve prolapse is not recommended (evidence  
level D, recommendation level weak).
recommendation 10.2
screening for intracranial aneurysms is not recommended for children with aDPKD 
(evidence level D, recommendation level weak).
recommendation 10.3
regular screening for liver cysts is not recommended in children with confirmed 
aDPKD (evidence level D, recommendation level weak).
recommendation 10.4
early referral to a specialized centre is recommended for the management of children 
with very- early-onset aDPKD or autosomal recessive polycystic kidney disease- like 
presentations (evidence level D, recommendation level moderate).
recommendation 10.5
referral to a specialized centre and multidisciplinary care is recommended for patients 
with TSC2/PKD1 contiguous gene syndrome (evidence level D, recommendation 
level weak).
Box 11 | psychosocial aspects
recommendation 11.1
Families should be encouraged to openly discuss their 
disease and future genetic risks with their children, for 
example, by provision of age- appropriate information 
and by providing support for family members in 
managing their own and their children’s emotions 
(evidence level B, recommendation level moderate).
recommendation 11.2
Care of teenagers with autosomal dominant polycystic 
kidney disease (aDPKD) should address lifestyle 
measures, as well as relevant medical issues of prevention 
(evidence level X, recommendation level moderate).
recommendation 11.3
Care of teenagers with aDPKD should address 
psychological issues and convey positive messages 
(evidence level X, recommendation level moderate).
recommendation 11.4
transition to adult nephrology care should follow best- 
practice guidelines (evidence level X, recommendation 
level moderate).
Conclusions
Although the main burden of disease in ADPKD does 
not occur until adulthood, a substantial proportion of 
paediatric and adolescent patients have treatable disease 
manifestations and a small percentage have symptomatic 
disease or very- early-onset disease in infancy. This con-
sensus group hopes that our recommendations will 
improve the care of children with or at risk of ADPKD. 
We recommend the provision of balanced counselling 
for families with respect to diagnostic screening, regular 
monitoring of blood pressure and proteinuria and the 
avoidance of frequent imaging to monitor cyst growth. 
We also provide guidance on managing complications, 
lifestyle interventions and psychosocial aspects. As 
the pharmacological management of adult ADPKD 
advances and the results of a paediatric trial of tolvaptan 
are pending, future challenges will include defining in 
medical, psychological and economic terms which 
patients will benefit from early initiation of treatment to 
delay disease progression.
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contraception products because of potential exacerbation 
of later liver disease.
Issues of genetic guilt or fear of the future disease 
course can have a substantial impact on the psycholog-
ical well- being of young people and families affected by 
ADPKD. Integrated care should therefore include active 
inquiry about anxieties and sources of psychological 
support. Positive messages that can be used to promote 
a proactive attitude towards disease management are, for 
example, ‘you are not ill’, ‘you have the opportunity and 
time to influence later outcome by preventive measures’ 
or ‘many career choices are open to you’. Young adults 
may also value discussion about wise disclosure of their 
renal disease to outsiders. Contact with affected peers 
via patient communities should be encouraged. Finally, 
reminding parents of their value as positive role models 
may be helpful.
Discontinuity of care because of transfer from paedi-
atric to adult nephrology care is an important risk factor 
for adverse outcome in more severely affected individu-
als. Local and international guidance on transition should 
be followed to prevent loss of medical follow- up166.
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